Expansion & Growth Bio-Rad’s recent product launches in process-scale chromatography (Foresight Pro columns with Nuvia resins) indicate ongoing capacity expansion and a push into scalable downstream processing for biopharma. This suggests sales opportunities for chromatography systems, resins, consumables, and related automation solutions tailored to manufacturing scale-up.

Diagnostics & QC With a portfolio spanning life science research and clinical diagnostics, Bio-Rad is expanding ready-to-use ddPCR kit offerings for QC workflows in biopharma, including cell and gene therapy. Target opportunities exist in QC kits, validated assay panels, and companion diagnostic workflows that streamline regulatory-compliant testing.

Therapeutics Enablement Development of Vericheck Kits on the QX700 platform signals emphasis on safer and more efficient advanced therapeutic development and manufacturing. This creates cross-sell potential for analytical solutions, assay reagents, and instrumentation that support gene therapy and biologics development pipelines.

Financial Momentum Strong quarterly performance with revenue beats and substantial comparable scale ($651M revenue in latest quarter; EPS well above expectations) indicates healthy demand and willingness to invest in Bio-Rad’s end-to-end solutions. Explore higher-value bundles, service contracts, and global distribution partnerships to capture incremental growth.

Global Footprint Bio-Rad operates globally with a large workforce and a broad customer network in life sciences and clinical diagnostics. Leverage this reach to propose regionalized training, support, and localized supply agreements, along with channel partnerships and strategic alliances to accelerate adoption of new kits, columns, and platforms.